The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
Latest Issue of the GIST Cancer Journal Released
The Life Raft Group is pleased to announce the release of the tenth issue of The GIST Cancer Journal, the official [...]
New York GDOL and Cancer Moonshot Summit: A Winning Combination
The LRG 2016 GIST Days of Learning Tour (GDOL) made a stop in New York City on June 29th. A GIST [...]
LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions
Loxo Oncology announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of [...]
Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the [...]
Thoughts on the Cancer Moonshot Summit
On July 29, 2016 I traveled to Howard University in Washington, DC to be a participant in Vice President Joe Biden’s [...]
Ignyta Announces Results for Potential New Cancer Treatment
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a [...]
14th NIH Pediatric and Wildtype GIST Clinic Convenes
If you have a mutation of any of the SDH subunits (a,b,c, or d), the next important question to ask is whether or not it is a germline mutation. (So far, data has indicated that 80% of SDH-deficient tumors are germline). The term "germline" means that the mutation is present in every cell of your body. Germline mutations are hereditary, and can be passed on to your children. For this reason, genetic testing and counseling could be informative for parents, siblings and other family members. If a family member tests positive for the mutation, this does not mean that they will get GIST.
Spring Appeal 2016 – We’re Not Finished Yet
"I'm glad I called the Life Raft Group. They rallied around me and told me I'm going to make it [...]
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
